Skip to main content
PMC home page
Infection and Immunity logoLink to Infection and Immunity
. 1996 Feb;64(2):576–584. doi: 10.1128/iai.64.2.576-584.1996

Development of Shigella sonnei live oral vaccines based on defined rfbInaba deletion mutants of Vibrio cholerae expressing the Shigella serotype D O polysaccharide.

D Favre 1, S J Cryz Jr 1, J F Viret 1
PMCID: PMC173804  PMID: 8550210

Abstract

Previous experimentation has highlighted a number of difficulties in the development of carrier-based bivalent vaccines (J.-F. Viret and D. Favre, Biologicals 22:361-372, 1994) In an attempt to obviate these carrier strains. Toward this aim, a series of defined rfbInaba deletion (delta rfbInaba) mutants of the cholera vaccine strain V. cholerae CVD103-HgR (O1 Inaba serotype) and derivative bearing the chromosomally integrated locus encoding the S. sonnei O-PS were constructed and characterized. The various mutations disrupt genes thought to be involved in either the synthesis of perosamine, the synthesis of 3-deoxy-L-glycero tetronic acid, or the O-PS transport functions together with synthesis of the perosamine synthetase. Some deletions were obtained only in strains expressing the heterologous lipopolysaccharide (LPS). Viable delta rfbInaba deletions in CVD103-HgR profoundly altered some of its phenotypic properties. The same deletions present in CVD103-HgR derivatives expressing the heterologous LPS affected their phenotypes only to a lesser extent. Only in strains in which perosamine synthesis was specifically abolished could high amounts of core-bound S. sonnei O-PS be synthesized. Two such strains (CH21, which expresses both the R1 core and the S. sonnei O-PS, and CH22, which expresses only the latter antigenic determinant) were further analyzed and were found to be indistinguishable from CVD103-HgR with regard to lack of enterotoxin activity, choleragenoid production, mercury resistance, pilin production, and, for CH22, motility. Mice immunized with CH22 produced high titers of S. sonnei O-PS-specific antibodies.

Full Text

The Full Text of this article is available as a PDF (313.0 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Attridge S. R., Daniels D., Morona J. K., Morona R. Surface co-expression of Vibrio cholerae and Salmonella typhi O-antigens on Ty21a clone EX210. Microb Pathog. 1990 Mar;8(3):177–188. doi: 10.1016/0882-4010(90)90045-r. [DOI] [PubMed] [Google Scholar]
  2. Attridge S. R., Dearlove C., Beyer L., van den Bosch L., Howles A., Hackett J., Morona R., LaBrooy J., Rowley D. Characterization and immunogenicity of EX880, a Salmonella typhi Ty21a-based clone which produces Vibrio cholerae O antigen. Infect Immun. 1991 Jul;59(7):2279–2284. doi: 10.1128/iai.59.7.2279-2284.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Black R. E. Epidemiology of diarrhoeal disease: implications for control by vaccines. Vaccine. 1993;11(2):100–106. doi: 10.1016/0264-410x(93)90002-f. [DOI] [PubMed] [Google Scholar]
  4. Black R. E., Levine M. M., Clements M. L., Losonsky G., Herrington D., Berman S., Formal S. B. Prevention of shigellosis by a Salmonella typhi-Shigella sonnei bivalent vaccine. J Infect Dis. 1987 Jun;155(6):1260–1265. doi: 10.1093/infdis/155.6.1260. [DOI] [PubMed] [Google Scholar]
  5. Brahmbhatt H. N., Lindberg A. A., Timmis K. N. Shigella lipopolysaccharide: structure, genetics, and vaccine development. Curr Top Microbiol Immunol. 1992;180:45–64. doi: 10.1007/978-3-642-77238-2_3. [DOI] [PubMed] [Google Scholar]
  6. Chambers S. P., Prior S. E., Barstow D. A., Minton N. P. The pMTL nic- cloning vectors. I. Improved pUC polylinker regions to facilitate the use of sonicated DNA for nucleotide sequencing. Gene. 1988 Aug 15;68(1):139–149. doi: 10.1016/0378-1119(88)90606-3. [DOI] [PubMed] [Google Scholar]
  7. Coster T. S., Killeen K. P., Waldor M. K., Beattie D. T., Spriggs D. R., Kenner J. R., Trofa A., Sadoff J. C., Mekalanos J. J., Taylor D. N. Safety, immunogenicity, and efficacy of live attenuated Vibrio cholerae O139 vaccine prototype. Lancet. 1995 Apr 15;345(8955):949–952. doi: 10.1016/s0140-6736(95)90698-3. [DOI] [PubMed] [Google Scholar]
  8. Cryz S. J., Jr, Pitt T. L., Fürer E., Germanier R. Role of lipopolysaccharide in virulence of Pseudomonas aeruginosa. Infect Immun. 1984 May;44(2):508–513. doi: 10.1128/iai.44.2.508-513.1984. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Czerkinsky C., Svennerholm A. M., Quiding M., Jonsson R., Holmgren J. Antibody-producing cells in peripheral blood and salivary glands after oral cholera vaccination of humans. Infect Immun. 1991 Mar;59(3):996–1001. doi: 10.1128/iai.59.3.996-1001.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Cárdenas L., Clements J. D. Oral immunization using live attenuated Salmonella spp. as carriers of foreign antigens. Clin Microbiol Rev. 1992 Jul;5(3):328–342. doi: 10.1128/cmr.5.3.328. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. DuPont H. L., Hornick R. B., Snyder M. J., Libonati J. P., Formal S. B., Gangarosa E. J. Immunity in shigellosis. I. Response of man to attenuated strains of Shigella. J Infect Dis. 1972 Jan;125(1):5–11. doi: 10.1093/infdis/125.1.5. [DOI] [PubMed] [Google Scholar]
  12. DuPont H. L., Hornick R. B., Snyder M. J., Libonati J. P., Formal S. B., Gangarosa E. J. Immunity in shigellosis. II. Protection induced by oral live vaccine or primary infection. J Infect Dis. 1972 Jan;125(1):12–16. doi: 10.1093/infdis/125.1.12. [DOI] [PubMed] [Google Scholar]
  13. Evans D. G., Evans D. J., Jr, Tjoa W. Hemagglutination of human group A erythrocytes by enterotoxigenic Escherichia coli isolated from adults with diarrhea: correlation with colonization factor. Infect Immun. 1977 Nov;18(2):330–337. doi: 10.1128/iai.18.2.330-337.1977. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Favre D. Improved phenol-based method for the isolation of DNA fragments from low melting temperature agarose gels. Biotechniques. 1992 Jul;13(1):22, 25-26. [PubMed] [Google Scholar]
  15. Fontaine A., Arondel J., Sansonetti P. J. Construction and evaluation of live attenuated vaccine strains of Shigella flexneri and Shigella dysenteriae 1. Res Microbiol. 1990 Sep-Oct;141(7-8):907–912. doi: 10.1016/0923-2508(90)90129-e. [DOI] [PubMed] [Google Scholar]
  16. Formal S. B., Hale T. L., Kapfer C., Cogan J. P., Snoy P. J., Chung R., Wingfield M. E., Elisberg B. L., Baron L. S. Oral vaccination of monkeys with an invasive Escherichia coli K-12 hybrid expressing Shigella flexneri 2a somatic antigen. Infect Immun. 1984 Nov;46(2):465–469. doi: 10.1128/iai.46.2.465-469.1984. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Forrest B. D., LaBrooy J. T. In vivo evidence of immunological masking of the Vibrio cholerae O antigen of a hybrid Salmonella typhi Ty21a-Vibrio cholerae oral vaccine in humans. Vaccine. 1991 Jul;9(7):515–520. doi: 10.1016/0264-410x(91)90039-9. [DOI] [PubMed] [Google Scholar]
  18. Fralick J. A., Burns-Keliher L. L. Additive effect of tolC and rfa mutations on the hydrophobic barrier of the outer membrane of Escherichia coli K-12. J Bacteriol. 1994 Oct;176(20):6404–6406. doi: 10.1128/jb.176.20.6404-6406.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Fuerst J. A., Perry J. W. Demonstration of lipopolysaccharide on sheathed flagella of Vibrio cholerae O:1 by protein A-gold immunoelectron microscopy. J Bacteriol. 1988 Apr;170(4):1488–1494. doi: 10.1128/jb.170.4.1488-1494.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Germanier R., Füer E. Isolation and characterization of Gal E mutant Ty 21a of Salmonella typhi: a candidate strain for a live, oral typhoid vaccine. J Infect Dis. 1975 May;131(5):553–558. doi: 10.1093/infdis/131.5.553. [DOI] [PubMed] [Google Scholar]
  21. Giannasca P. J., Neutra M. R. Interactions of microorganisms with intestinal M cells: mucosal invasion and induction of secretory immunity. Infect Agents Dis. 1993 Aug;2(4):242–248. [PubMed] [Google Scholar]
  22. Gustafsson B., Holme T. Monoclonal antibodies against group- and type-specific lipopolysaccharide antigens of Vibrio cholerae O:1. J Clin Microbiol. 1983 Sep;18(3):480–485. doi: 10.1128/jcm.18.3.480-485.1983. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Hartman A. B., Ruiz M. M., Schultz C. L. Molecular analysis of variant plasmid forms of a bivalent Salmonella typhi-Shigella sonnei vaccine strain. J Clin Microbiol. 1991 Jan;29(1):27–32. doi: 10.1128/jcm.29.1.27-32.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Herrington D. A., Van de Verg L., Formal S. B., Hale T. L., Tall B. D., Cryz S. J., Tramont E. C., Levine M. M. Studies in volunteers to evaluate candidate Shigella vaccines: further experience with a bivalent Salmonella typhi-Shigella sonnei vaccine and protection conferred by previous Shigella sonnei disease. Vaccine. 1990 Aug;8(4):353–357. doi: 10.1016/0264-410x(90)90094-3. [DOI] [PubMed] [Google Scholar]
  25. Jann B., Jann K., Beyaert G. O. 2-Amino-2,6-dideoxy-d-glucose (D-quinovosamine): a constituent of the lipopolysaccharides of Vibrio cholerae. Eur J Biochem. 1973 Sep 3;37(3):531–534. doi: 10.1111/j.1432-1033.1973.tb03015.x. [DOI] [PubMed] [Google Scholar]
  26. Jansson P. E., Lindberg A. A., Lindberg B., Wollin R. Structural studies on the hexose region of the core in lipopolysaccharides from Enterobacteriaceae. Eur J Biochem. 1981 Apr;115(3):571–577. doi: 10.1111/j.1432-1033.1981.tb06241.x. [DOI] [PubMed] [Google Scholar]
  27. Kabir S., Ali S. Characterization of surface properties of Vibrio cholerae. Infect Immun. 1983 Mar;39(3):1048–1058. doi: 10.1128/iai.39.3.1048-1058.1983. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Kaper J. B., Morris J. G., Jr, Levine M. M. Cholera. Clin Microbiol Rev. 1995 Jan;8(1):48–86. doi: 10.1128/cmr.8.1.48. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Keen N. T., Tamaki S., Kobayashi D., Trollinger D. Improved broad-host-range plasmids for DNA cloning in gram-negative bacteria. Gene. 1988 Oct 15;70(1):191–197. doi: 10.1016/0378-1119(88)90117-5. [DOI] [PubMed] [Google Scholar]
  30. Kenne L., Lindberg B., Unger P., Gustafsson B., Holme T. Structural studies of the Vibrio cholerae O-antigen. Carbohydr Res. 1982 Mar 1;100:341–349. doi: 10.1016/s0008-6215(00)81047-2. [DOI] [PubMed] [Google Scholar]
  31. Ketley J. M., Michalski J., Galen J., Levine M. M., Kaper J. B. Construction of genetically marked Vibrio cholerae O1 vaccine strains. FEMS Microbiol Lett. 1993 Jul 15;111(1):15–21. doi: 10.1111/j.1574-6968.1993.tb06355.x. [DOI] [PubMed] [Google Scholar]
  32. Kondo S., Iguchi T., Hisatsune K. A comparative study of the sugar composition of lipopolysaccharides isolated from Vibrio cholerae, 'Vibrio albensis' and Vibrio metschnikovii. J Gen Microbiol. 1988 Jun;134(6):1699–1705. doi: 10.1099/00221287-134-6-1699. [DOI] [PubMed] [Google Scholar]
  33. Kärnell A., Li A., Zhao C. R., Karlsson K., Nguyen B. M., Lindberg A. A. Safety and immunogenicity study of the auxotrophic Shigella flexneri 2a vaccine SFL1070 with a deleted aroD gene in adult Swedish volunteers. Vaccine. 1995 Jan;13(1):88–99. doi: 10.1016/0264-410x(95)80017-8. [DOI] [PubMed] [Google Scholar]
  34. Laird M. W., Kloser A. W., Misra R. Assembly of LamB and OmpF in deep rough lipopolysaccharide mutants of Escherichia coli K-12. J Bacteriol. 1994 Apr;176(8):2259–2264. doi: 10.1128/jb.176.8.2259-2264.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Levine M. M., Kaper J. B. Live oral vaccines against cholera: an update. Vaccine. 1993;11(2):207–212. doi: 10.1016/0264-410x(93)90019-t. [DOI] [PubMed] [Google Scholar]
  36. Lindberg A. A., Pál T. Strategies for development of potential candidate Shigella vaccines. Vaccine. 1993;11(2):168–179. doi: 10.1016/0264-410x(93)90014-o. [DOI] [PubMed] [Google Scholar]
  37. Manning P. A., Stroeher U. H., Karageorgos L. E., Morona R. Putative O-antigen transport genes within the rfb region of Vibrio cholerae O1 are homologous to those for capsule transport. Gene. 1995 May 26;158(1):1–7. doi: 10.1016/0378-1119(95)00124-o. [DOI] [PubMed] [Google Scholar]
  38. Maurelli A. T., Sansonetti P. J. Genetic determinants of Shigella pathogenicity. Annu Rev Microbiol. 1988;42:127–150. doi: 10.1146/annurev.mi.42.100188.001015. [DOI] [PubMed] [Google Scholar]
  39. Nikaido H., Vaara M. Molecular basis of bacterial outer membrane permeability. Microbiol Rev. 1985 Mar;49(1):1–32. doi: 10.1128/mr.49.1.1-32.1985. [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. Noriega F. R., Wang J. Y., Losonsky G., Maneval D. R., Hone D. M., Levine M. M. Construction and characterization of attenuated delta aroA delta virG Shigella flexneri 2a strain CVD 1203, a prototype live oral vaccine. Infect Immun. 1994 Nov;62(11):5168–5172. doi: 10.1128/iai.62.11.5168-5172.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  41. Orr N., Robin G., Cohen D., Arnon R., Lowell G. H. Immunogenicity and efficacy of oral or intranasal Shigella flexneri 2a and Shigella sonnei proteosome-lipopolysaccharide vaccines in animal models. Infect Immun. 1993 Jun;61(6):2390–2395. doi: 10.1128/iai.61.6.2390-2395.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  42. Owen R. L., Pierce N. F., Apple R. T., Cray W. C., Jr M cell transport of Vibrio cholerae from the intestinal lumen into Peyer's patches: a mechanism for antigen sampling and for microbial transepithelial migration. J Infect Dis. 1986 Jun;153(6):1108–1118. doi: 10.1093/infdis/153.6.1108. [DOI] [PubMed] [Google Scholar]
  43. Redmond J. W. 4-Amino-4,6-dideoxy-D-mannose (D-perosamine): a component of the lipopolysaccharide of Vibrio cholerae 569B (Inaba). FEBS Lett. 1975 Feb 1;50(2):147–149. doi: 10.1016/0014-5793(75)80476-5. [DOI] [PubMed] [Google Scholar]
  44. Ried G., Hindennach I., Henning U. Role of lipopolysaccharide in assembly of Escherichia coli outer membrane proteins OmpA, OmpC, and OmpF. J Bacteriol. 1990 Oct;172(10):6048–6053. doi: 10.1128/jb.172.10.6048-6053.1990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  45. Sack D. A., Sack R. B. Test for enterotoxigenic Escherichia coli using Y-1 adrenal cells in miniculture. Infect Immun. 1975 Feb;11(2):334–336. doi: 10.1128/iai.11.2.334-336.1975. [DOI] [PMC free article] [PubMed] [Google Scholar]
  46. Salvi R. J., Ahroon W., Saunders S. S., Arnold S. A. Evoked potentials: computer-automated threshold-tracking procedure using an objective detection criterion. Ear Hear. 1987 Jun;8(3):151–156. [PubMed] [Google Scholar]
  47. Sandlin R. C., Lampel K. A., Keasler S. P., Goldberg M. B., Stolzer A. L., Maurelli A. T. Avirulence of rough mutants of Shigella flexneri: requirement of O antigen for correct unipolar localization of IcsA in the bacterial outer membrane. Infect Immun. 1995 Jan;63(1):229–237. doi: 10.1128/iai.63.1.229-237.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  48. Sansonetti P. J., Kopecko D. J., Formal S. B. Shigella sonnei plasmids: evidence that a large plasmid is necessary for virulence. Infect Immun. 1981 Oct;34(1):75–83. doi: 10.1128/iai.34.1.75-83.1981. [DOI] [PMC free article] [PubMed] [Google Scholar]
  49. Seid R. C., Jr, Kopecko D. J., Sadoff J. C., Schneider H., Baron L. S., Formal S. B. Unusual lipopolysaccharide antigens of a Salmonella typhi oral vaccine strain expressing the Shigella sonnei form I antigen. J Biol Chem. 1984 Jul 25;259(14):9028–9034. [PubMed] [Google Scholar]
  50. Taylor D. N., Killeen K. P., Hack D. C., Kenner J. R., Coster T. S., Beattie D. T., Ezzell J., Hyman T., Trofa A., Sjogren M. H. Development of a live, oral, attenuated vaccine against El Tor cholera. J Infect Dis. 1994 Dec;170(6):1518–1523. doi: 10.1093/infdis/170.6.1518. [DOI] [PubMed] [Google Scholar]
  51. Taylor D. N., Trofa A. C., Sadoff J., Chu C., Bryla D., Shiloach J., Cohen D., Ashkenazi S., Lerman Y., Egan W. Synthesis, characterization, and clinical evaluation of conjugate vaccines composed of the O-specific polysaccharides of Shigella dysenteriae type 1, Shigella flexneri type 2a, and Shigella sonnei (Plesiomonas shigelloides) bound to bacterial toxoids. Infect Immun. 1993 Sep;61(9):3678–3687. doi: 10.1128/iai.61.9.3678-3687.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  52. Viret J. F., Bruderer U., Lang A. B. Characterization of the Shigella serotype D (S. sonnei) O polysaccharide and the enterobacterial R1 lipopolysaccharide core by use of mouse monoclonal antibodies. Infect Immun. 1992 Jul;60(7):2741–2747. doi: 10.1128/iai.60.7.2741-2747.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  53. Viret J. F., Cryz S. J., Jr, Lang A. B., Favre D. Molecular cloning and characterization of the genetic determinants that express the complete Shigella serotype D (Shigella sonnei) lipopolysaccharide in heterologous live attenuated vaccine strains. Mol Microbiol. 1993 Jan;7(2):239–252. doi: 10.1111/j.1365-2958.1993.tb01115.x. [DOI] [PubMed] [Google Scholar]
  54. Viret J. F., Favre D. Bivalent vaccines against bacterial enteropathogens: construction of live attenuated vaccine strains with two O-serotype specificities. Biologicals. 1994 Dec;22(4):361–372. doi: 10.1006/biol.1994.1055. [DOI] [PubMed] [Google Scholar]

Articles from Infection and Immunity are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES